These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 10215956

  • 1. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery.
    Schulman S, Wallensten R, White B, Smith OP.
    Haemophilia; 1999 Mar; 5(2):96-100. PubMed ID: 10215956
    [Abstract] [Full Text] [Related]

  • 2. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
    Hoots WK, Leissinger C, Stabler S, Schwartz BA, White G, Dasani H, Massion C, Negrier C, Schindel F, Schulman S.
    Haemophilia; 2003 Mar; 9(2):164-72. PubMed ID: 12614367
    [Abstract] [Full Text] [Related]

  • 3. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J, Peynet J, Chambost H, Négrier C, Briquel ME, Claeyssens S, Derlon-Borel A, Guérois C, Caron C, Scherrmann JM, Debray M, Bridey F.
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M, Skotnicki AB, Colovic M, Jinca C, Klukowska A, Laguna P, Wolf DM.
    Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
    [Abstract] [Full Text] [Related]

  • 5. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Cabrera N, Aznar JA, Woodward MK, Páez A.
    Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
    [Abstract] [Full Text] [Related]

  • 6. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañes M, Paez A.
    Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
    [Abstract] [Full Text] [Related]

  • 7. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
    Escobar MA, Tehranchi R, Karim FA, Caliskan U, Chowdary P, Colberg T, Giangrande P, Giermasz A, Mancuso ME, Serban M, Tsay W, Mahlangu JN.
    Haemophilia; 2017 Jan; 23(1):67-76. PubMed ID: 27480487
    [Abstract] [Full Text] [Related]

  • 8. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G, Bade A, Haubold K, Overberg D, Masurat S, Moorthi C.
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA, Cabrera N, Matysiak M, Zawilska K, Gercheva L, Antonov A, Montañés M, Páez AM, Lissitchkov T.
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis.
    Quon DV, Logan L.
    Haemophilia; 2011 Jan; 17(1):e196-201. PubMed ID: 20618876
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J, Lissitchkov T, Stasyshyn O, Mamonov V, Rusen L, Lamas JL, Oh MS, Chapman M, Fritsch S, Pavlova BG, Wong WY, Abbuehl BE.
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [Abstract] [Full Text] [Related]

  • 12. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies.
    Mauser-Bunschoten EP, Kleine Budde I, Lopaciuk S, Koopman MM, Van Der Meer FJ, Novàkovà IR, Ypma P, Van Der Linden PW, Windyga J, Strengers PF.
    Haemophilia; 2011 May; 17(3):439-45. PubMed ID: 21362109
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C, Abdul Karim F, Lepatan LM, Lienhart A, López-Fernández MF, Mahlangu J, Pabinger I, Li Y, Wolko D, Voigt C, Jacobs I, Santagostino E.
    Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
    [Abstract] [Full Text] [Related]

  • 14. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang H, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, Allen G, Pierce GF, Robinson B.
    Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
    [Abstract] [Full Text] [Related]

  • 15. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010.
    Uprichard J, Adamidou D, Goddard NJ, Mann HA, Yee TT.
    Haemophilia; 2012 Jan; 18(1):46-9. PubMed ID: 21545378
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
    Collins PW, Quon DVK, Makris M, Chowdary P, Kempton CL, Apte SJ, Ramanan MV, Hay CRM, Drobic B, Hua Y, Babinchak TJ, Gomperts ED.
    Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion.
    Tagariello G, Davoli PG, Gajo GB, De Biasi E, Risato R, Baggio R, Traldi A.
    Haemophilia; 1999 Nov; 5(6):426-30. PubMed ID: 10583530
    [Abstract] [Full Text] [Related]

  • 18. A retrospective survey on the safety of Replenine, a high-purity factor IX concentrate.
    Gascoigne EW, Dash CH, Harman C, Wilmot D.
    Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):187-95. PubMed ID: 15072119
    [Abstract] [Full Text] [Related]

  • 19. Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP.
    Curtin J, Santagostino E, Karim FA, Li Y, Seifert W, Négrier C.
    Thromb Res; 2020 Apr; 188():85-89. PubMed ID: 32109773
    [Abstract] [Full Text] [Related]

  • 20. Secondary prophylaxis with factor IX concentrates: continuous infusion.
    Morfini M.
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s21-5. PubMed ID: 19105506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.